Healthcare Doesn’t Have a Capital Problem. It Has a Capital Efficiency Problem

Healthcare has a capital problem – but not the one most people talk about.

The industry’s attention tends to fix on the headline numbers – drug development costs running into the hundreds of millions, device commercialization requiring tens of millions more, and digital health funding cycles that have tightened drastically in recent years. The assumed solution is more capital, more runway, and an increased investor appetite.

But the more I work with early-stage health innovators, the more I’ve come to realize the problem isn’t a shortage of capital – it’s the cost of misdirected capital, and the time burned testing assumptions that an experienced operator could have corrected in a single conversation.

Payer operations, to use one example, can be a black hole for founders. Every health plan carries its own strategic priorities, member population dynamics, and internal decision-making logic that simply isn’t legible from the outside. A founder can spend a year (and significant capital) building toward a partnership strategy that is architecturally flawed from the start.

I’ve seen this play out firsthand. A startup enters a program with a well-constructed hypothesis about how to work with health plans. After immersion in how plans actually operate, the founder doesn’t just refine the strategy, they abandon it entirely and pivot to a different target market. That pivot, which may take 12-18 months of costly market testing to arrive at independently, instead happens in months. The founder ultimately divulges that the accelerator experience saved them more time than they can calculate – and in early-stage companies, time is the resource you can never recover.

This isn’t a mentorship story – it’s a capital efficiency story.

The Actual Impact of Accelerators

The traditional framing of accelerators (mentorship, network, demo days) undersells what a well-structured corporate program actually does. When a startup is embedded inside a functioning health system or payer organization, they gain something no pitch competition can offer – a front row seat to real clinical workflows, procurement realities, reimbursement constraints, and the decision-makers who navigate them daily.

This compression of learning has measurable trickle-down effects. Observational study shows accelerator participation is associated with stronger fundraising outcomes and higher venture survival rates. In healthcare specifically, studies on digital health adoption highlight persistent barriers around procurement, workflow integration, and stakeholder trust – exactly the barriers that early corporate immersion helps dismantle.

The results show up in investor behavior, too. Healthcare-specific accelerator experience has become a credibility signal that generic programs can’t replicate. Investors increasingly recognize that a startup that has been stress-tested inside a real health system has confronted industry reality, not just pitch-deck logic. 

Measurable – and Noticeable – Results

The proof lives in outcomes. Companies that move through well-designed healthcare accelerators don’t just survive at higher rates – they demonstrate clinical and operational impact that standalone startups rarely achieve at the same stage.

One company participating in a healthcare accelerator entered a quality improvement partnership with a regional health plan focused on members with uncontrolled type 2 diabetes. Within 90 days, patients saw an average two-point decrease in hemoglobin A1c – outpacing traditional and virtual-only solutions by more than 50%. 

Another launched a technology pilot covering hundreds of daily interactions within a Medicare population; strong internal demand drove an expanded enterprise contract well beyond the original scope. A third is entering a full enterprise deployment in 2026 to replace a fragmented, manual compliance process with a unified, real-time system.

These outcomes don’t happen by accident. They happen because the startup and the health system built a shared understanding of the problem long before a contract was signed.

The Real ROI

There’s a second layer that rarely gets discussed in conversations about accelerator ROI, and it may be the more durable one.

When we invited our workforce to take on advisory roles with accelerator startups, more than 160 employees responded – out of an organization of roughly 3,000. That response rate said something important about what a curious, forward-thinking workforce is hungry for – the chance to engage with new ideas, contribute beyond their immediate function, and be part of building something. 

That engagement doesn’t just benefit the startups. It transforms the organization. Employees who work alongside early-stage founders develop an instinct for vetting innovation, a tolerance for ambiguity, and a fluency in what it actually takes to build and deploy new solutions in complex systems. Legacy systems and startup speed are genuinely incompatible if you don’t build the internal muscle to bridge them. The accelerator is where that muscle gets built – and that capability becomes a lasting competitive asset.

The Framework for the Future

Healthcare is right to be risk-averse. The stakes demand it – such as clinical outcomes, financial stability, and patient trust. But risk aversion applied to innovation infrastructure is a losing game. It preserves the status quo while the cost of delay compounds quietly in the background.

The industry needs a sharper framework for evaluating accelerator investment – one that goes beyond demo day metrics and measures what actually matters – time to revenue for portfolio companies, cost avoided through earlier regulatory and operational alignment, follow-on capital raised post-program, and pilot-to-contract conversion rates.

By those measures, a well-designed corporate accelerator isn’t a line item in the innovation budget. It’s risk mitigation infrastructure – the kind that promises returns on both sides of the partnership, and that healthcare can no longer afford to treat as optional.